Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer
Open Access
- 2 November 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Abstract
To investigate whether very low mammographic breast density (VLD), HER2, and hormone receptor status holds any prognostic significance within the different prognostic categories of the widely used Nottingham Prognostic Index (NPI). We also aimed to see whether these factors could be incorporated into the NPI in an effort to enhance its performance. This study included 270 patients with newly diagnosed invasive breast cancer. Patients with mammographic breast density of <10 % were considered as VLD. In this study, we compared the performance of NPI with and without VLD, HER2, ER and PR. Cox multivariate analysis, time-dependent receiver operating characteristic curve (tdROC), concordance index (c-index) and prediction error (0.632+ bootstrap estimator) were used to derive an updated version of NPI. Both mammographic breast density (VLD) (p < 0.001) and HER2 status (p = 0.049) had a clinically significant effect on the disease free survival of patients in the intermediate and high risk groups of the original NPI classification. The incorporation of both factors (VLD and HER2 status) into the NPI provided improved patient outcome stratification by decreasing the percentage of patients in the intermediate prognostic groups, moving a substantial percentage towards the low and high risk prognostic groups. Very low density (VLD) and HER2 positivity were prognostically significant factors independent of the NPI. Furthermore, the incorporation of VLD and HER2 to the NPI served to enhance its accuracy, thus offering a readily available and more accurate method for the evaluation of patient prognosis.Keywords
Funding Information
- Kuopio University Hospital VTR Fund (5063525, 5063532, 5063525, 5063532)
- Instrumentarium foundation
- Cancer Center of Eastern Finland
- Radiological Society of Finland
- Finnish Oncological Society
- Inkeri and Mauri Vänskä Foundation
- Suomen Lääketieteen Säätiö (FI)
- Suomen Lääketieteen Säätiö
- Pohjois-Savon Syöpä yhdistys
- Syöpäjärjestöt
- Syöpäjärjestöt
- Syöpäjärjestöt
This publication has 43 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Application of microarray in breast cancer: An overviewJournal of Pharmacy and Bioallied Sciences, 2012
- Heterogeneity in breast cancerJournal of Clinical Investigation, 2011
- Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistryBreast Cancer Research, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer TrialJournal of Clinical Oncology, 2009
- An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United KingdomBritish Journal of Cancer, 2009
- Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999European Journal of Cancer, 2007
- “Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilersEuropean Journal of Cancer, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987